Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

Phase 3 Terminated 284 enrolled Viatris Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of adolescents (ages 13-17) with schizophrenia

Timeline

Start: 2006-04
Primary completion: 2009-03
Completion: 2009-03

Publications

Findling RL, Cavus I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK, DelBello MP. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study. J Child Adolesc Psychopharmacol. 2013 Oct;23(8):531-44. doi: 10.1089/cap.2012.0068. Epub 2013 Oct 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ziprasidone	Small molecule	20 mg	Oral
Comparator	Ziprasidone	Small molecule	40 mg	Oral
Comparator	Ziprasidone	Small molecule	60 mg	Oral
Comparator	Ziprasidone	Small molecule	80 mg	Oral

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

Summary

Timeline

Publications

Drugs

Indications